CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.
  
  LEARNING OBJECTIVES

  • Identify patients with newly diagnosed DLBCL for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate.
  • Apply available clinical research findings in the formation of evidence-based approaches for the treatment of relapsed/refractory (R/R) DLBCL in patients who are unfit for intensive therapy.
  • Evaluate the mechanisms of action, available clinical trial findings and spectrum and frequency of toxicities associated with various CD19-directed therapies approved for R/R DLBCL.
  • Appraise the biological rationale for, recently presented research findings with and the potential role of CD30-targeted antibody-drug conjugate-based therapy for R/R DLBCL.
  • Consider published research data with and the current clinical role of bispecific antibodies targeting CD20 x CD3 in R/R DLBCL.
  • Counsel appropriate patients regarding the potential benefits of participation in clinical studies evaluating novel agents and strategies for DLBCL.

  

  ACCREDITATION STATEMENT
  In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
  
  PHYSICIAN CONTINUING MEDICAL EDUCATION
  Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
  
  Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SOHO2024/DLBCL/Video/CME.
  
  DISCLOSURE & CONFLICT OF INTEREST POLICY
  Medical Learning Institute, Inc. (MLI) and Research To Practice (RTP) are committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Grzegorz S Nowakowski, MD
  Professor of Medicine and Oncology
  Chair, Lymphoid Malignancy Group
  Enterprise Deputy Director, Clinical Research
  Mayo Clinic Comprehensive Cancer Center
  Vice-Chair, Division of Hematology
  Mayo Clinic
  Rochester, Minnesota
  
  Consulting Agreements: AbbVie Inc, ADC Therapeutics, Bantam Pharmaceutical, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Curis Inc, Daiichi Sankyo Inc, Debiopharm, F Hoffmann-La Roche Ltd, Fate Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MEI Pharma Inc, MorphoSys, Ryvu Therapeutics, Seagen Inc, Selvita, TG Therapeutics Inc, Zai Lab.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Clinical Professor of Medicine
  Division of Medical Oncology
  University of British Columbia
  Podcast Editor, Blood
  Vancouver, British Columbia, Canada
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Seagen Inc, Teva Oncology; Contracted Research: Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: CARGO Therapeutics.
  
  MODERATOR
  Christopher Flowers, MD, MS
  Division Head, Division of Cancer Medicine
  Chair, Professor, Department of Lymphoma/Myeloma
  John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.
  
  All of the relevant financial relationships of individuals for this activity have been mitigated.
  
  PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
  
  SUPPORT STATEMENT
  This CE activity is supported through educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, and Incyte Corporation.
  
  Release date: October 9, 2024
  Expiration date: October 10, 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.